Despite the lack of pretreatment data, the persistence of an IFN signature in the patient cells is in line with previous reports where baricitinib treatment demonstrated efficacy in reducing clinical manifestations in other SAVI patients, although incomplete inhibition of type I IFN signaling was observed (Sanchez et al., 2018; Fremond et al., 2016). This evidence concerns the gene IFNA1 and STING-associated vasculopathy with onset in infancy.